{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:19:01Z","timestamp":1778008741303,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: This study aimed to assess the impact of clinical prognostic factors and propose a prognostic score that aids the clinician\u2019s decision in estimating the risk for patients in clinical practice. Materials and Methods: The study included 195 patients diagnosed with ovarian adenocarcinoma. The therapeutic strategy involved multidisciplinary decisions: surgery followed by adjuvant chemotherapy (80%), neoadjuvant chemotherapy followed by surgery (16.4%), and only chemotherapy in selected cases (3.6%). Results: After a median follow-up of 68 months, in terms of progression-free survival (PFS) and overall survival (OS), Eastern Cooperative Oncology Group (ECOG) performance status of 1 and 2 vs. 0 (hazard ratio\u2014HR = 2.71, 95% confidence interval\u2014CI, 1.96\u20133.73, p &lt; 0.001 for PFS and HR = 3.19, 95%CI, 2.20\u20134.64, p &lt; 0.001 for OS), menopausal vs. premenopausal status (HR = 2.02, 95%CI, 1.35\u20133,0 p &lt; 0.001 and HR = 2.25, 95%CI = 1.41\u20133.59, p &lt; 0.001), ascites (HR = 1.95, 95%CI 1.35\u20132.80, p = 0.03, HR = 2.31, 95%CI = 1.52\u20133.5, p &lt; 0.007), residual disease (HR = 5.12, 95%CI 3.43\u20137.65, p &lt; 0.0001 and HR = 4.07, 95%CI = 2.59\u20136.39, p &lt; 0.0001), and thrombocytosis (HR = 2.48 95%CI = 1.72\u20133.58, p &lt; 0.0001, HR = 3.33, 95%CI = 2.16\u20135.13, p &lt; 0.0001) were associated with a poor prognosis. An original prognostic score including these characteristics was validated using receiver operating characteristic (ROC) curves (area under the curve\u2014AUC = 0.799 for PFS and AUC = 0.726 for OS, p &lt; 0.001). The median PFS for patients with none, one, two, three, or four (or more) prognostic factors was not reached, 70, 36, 20, and 12 months, respectively. The corresponding median overall survival (OS) was not reached, 108, 77, 60, and 34 months, respectively. Conclusions: Several negative prognostic factors were identified: ECOG performance status \u2265 1, the presence of ascites and residual disease after surgery, thrombocytosis, and menopausal status. These led to the development of an original prognostic score that can be helpful in clinical practice.<\/jats:p>","DOI":"10.3390\/medicina59020229","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T01:58:59Z","timestamp":1674784739000},"page":"229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation of a New Prognostic Score in Patients with Ovarian Adenocarcinoma"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-7067","authenticated-orcid":false,"given":"Oana","family":"Trifanescu","sequence":"first","affiliation":[{"name":"Discipline of Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"},{"name":"Department of Radiotherapy, \u201cProf. Dr. Al. Trestioreanu\u201d Institute of Oncology, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0454-0453","authenticated-orcid":false,"given":"Radu","family":"Mitrica","sequence":"additional","affiliation":[{"name":"Discipline of Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"},{"name":"Department of Radiotherapy, \u201cProf. Dr. Al. Trestioreanu\u201d Institute of Oncology, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0414-1607","authenticated-orcid":false,"given":"Laurentia","family":"Gales","sequence":"additional","affiliation":[{"name":"Discipline of Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"},{"name":"Department of Oncology, \u201cProf. Dr. Al. Trestioreanu\u201d Institute of Oncology, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serban","family":"Marinescu","sequence":"additional","affiliation":[{"name":"Department of Surgery, \u201cProf. Dr. Al. Trestioreanu\u201d Institute of Oncology, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Motas","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, \u201cProf. Dr. Al. Trestioreanu\u201d Institute of Oncology, 022328 Bucharest, Romania"},{"name":"Discipline of Thoracic Surgery, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Trifanescu","sequence":"additional","affiliation":[{"name":"Discipline of Endocrinology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 011863 Bucharest, Romania"},{"name":"\u201cC.I. Parhon\u201d Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-7984","authenticated-orcid":false,"given":"Laura","family":"Rebegea","sequence":"additional","affiliation":[{"name":"Discipline of Oncology, Faculty of Medicine and Pharmacy, \u201cDunarea de Jos\u201d University, 800010 Galati, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4293-0428","authenticated-orcid":false,"given":"Mirela","family":"Gherghe","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, \u201cProf. Dr. Al. Trestioreanu\u201d Institute of Oncology, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragos","family":"Georgescu","sequence":"additional","affiliation":[{"name":"\u201cDr. Ion Cantacuzino\u201d Department of Surgery, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 030167 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Serbanescu","sequence":"additional","affiliation":[{"name":"Discipline of Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"},{"name":"Department of Radiotherapy, \u201cProf. Dr. Al. Trestioreanu\u201d Institute of Oncology, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haj","family":"Bashar","sequence":"additional","affiliation":[{"name":"Department for Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, 66421 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serban","family":"Dragosloveanu","sequence":"additional","affiliation":[{"name":"Discipline of Orthopedics, \u201cFoisor\u201d Orthopedics Hospital, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1798-853X","authenticated-orcid":false,"given":"Daniel","family":"Cristian","sequence":"additional","affiliation":[{"name":"Discipline of Surgery, Coltea Clinical Hospital, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"Anghel","sequence":"additional","affiliation":[{"name":"Discipline of Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"},{"name":"Department of Radiotherapy, \u201cProf. Dr. Al. Trestioreanu\u201d Institute of Oncology, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the Ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e25271","DOI":"10.1097\/MD.0000000000025271","article-title":"Long-Term Oncological Outcome in Patients with Cervical Cancer after 3 Trimodality Treatment (Radiotherapy, Platinum-Based Chemotherapy, and Robotic Surgery)","volume":"100","author":"Trifanescu","year":"2021","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer Statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bristow, R.E., Tomacruz, R.S., Armstrong, D.K., Trimble, E.L., and Montz, F.J. (2002). Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma during the Platinum Era: A Meta-Analysis, Centre for Reviews and Dissemination.","DOI":"10.1200\/JCO.2002.20.5.1248"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Trifanescu, O.G., Gales, L.N., Tanase, B.C., Marinescu, S.A., Trifanescu, R.A., Gruia, I.M., Paun, M.A., Rebegea, L., Mitrica, R., and Serbanescu, L. (2023). Prognostic Role of Vascular Endothelial Growth Factor and Correlation with Oxidative Stress Markers in Locally Advanced and Metastatic Ovarian Cancer Patients. Diagnostics, 13.","DOI":"10.3390\/diagnostics13010166"},{"key":"ref_7","first-page":"1320","article-title":"A Randomized Clinical Trial of Cisplatin\/Paclitaxel Versus Carboplatin\/Paclitaxel as First-Line Treatment of Ovarian Cancer","volume":"95","year":"2003","journal-title":"Cancer Spectrum Knowl. Environ."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_9","first-page":"1127","article-title":"Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d\u2019Investigateurs Nationaux Pour l\u2019Etude Des Cancers Ovariens","volume":"24","author":"Weber","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_11","first-page":"14","article-title":"Menopause and Ovarian Cancer Risk: Mechanisms and Experimental Support","volume":"2","author":"Rampersad","year":"2015","journal-title":"Am. J. Clin. Exp. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.0001-6349.2004.00550.x","article-title":"Review of Epidemiological Evidence for Reproductive and Hormonal Factors in Relation to the Risk of Epithelial Ovarian Malignancies","volume":"83","author":"Riman","year":"2004","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_13","first-page":"353","article-title":"Clinical Prognostic Factors in pre- and Post-Menopausal Women with Ovarian Carcinoma","volume":"14","author":"Trifanescu","year":"2018","journal-title":"Acta Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/GME.0000000000000976","article-title":"Different Features of the Histopathological Subtypes of Ovarian Tumors in Pre- and Postmenopausal Women","volume":"24","author":"Jung","year":"2017","journal-title":"Menopause"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic Thrombocytosis in Ovarian Cancer","volume":"366","author":"Stone","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13048-019-0544-y","article-title":"Combined Score of Pretreatment Platelet Count and CA125 Level (PLT-CA125) Stratified Prognosis in Patients with FIGO Stage IV Epithelial Ovarian Cancer","volume":"12","author":"Chen","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/08941939.2020.1827314","article-title":"Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study","volume":"35","author":"Dai","year":"2022","journal-title":"J. Investig. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/aogs.13453","article-title":"Impact of Residual Disease on Overall Survival in Women with Federation of Gynecology and Obstetrics Stage IIIB-IIIC vs Stage IV Epithelial Ovarian Cancer after Primary Surgery","volume":"98","author":"Schnack","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2015.12.007","article-title":"Prognostic Impact of Debulking Surgery and Residual Tumor in Patients with Epithelial Ovarian Cancer FIGO Stage IV","volume":"140","author":"Ataseven","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological Chemotherapy Response Score Is Prognostic in Tubo-Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis of Individual Patient Data","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fonc.2019.00778","article-title":"Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease","volume":"9","author":"Santoro","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1245\/s10434-020-08649-6","article-title":"The Peritoneal Cancer Index Is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer","volume":"28","author":"Lomnytska","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ejso.2021.03.233","article-title":"Peroperative Scoring Systems for Predicting the Outcome of Cytoreductive Surgery in Advanced-Stage Ovarian Cancer\u2014A Systematic Review","volume":"47","author":"Engbersen","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2147\/CMAR.S161876","article-title":"Prognostic Significance of Preoperative Serum Albumin in Epithelial Ovarian Cancer Patients: A Systematic Review and Dose\u2013Response Meta-Analysis of Observational Studies","volume":"10","author":"Ge","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/aje\/kwn006","article-title":"Hormonal Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal Women","volume":"167","author":"Moorman","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","article-title":"Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis from the Ovarian Cancer Cohort Consortium","volume":"34","author":"Wentzensen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hu, J., Jiao, X., Zhu, L., Guo, H., and Wu, Y. (2020). Establishment and Verification of the Nomogram That Predicts the 3-Year Recurrence Risk of Epithelial Ovarian Carcinoma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07402-2"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ygyno.2012.11.002","article-title":"The Prognostic Value of Vascular Endothelial Growth Factor in Ovarian Cancer: A Systematic Review and Meta-Analysis","volume":"128","author":"Yu","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.medici.2014.09.001","article-title":"Significance of Blood Serum Catalase Activity and Malondialdehyde Level for Survival Prognosis of Ovarian Cancer Patients","volume":"50","author":"Stukas","year":"2014","journal-title":"Medicina"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/IGC.0000000000001027","article-title":"Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer","volume":"27","author":"Komatsu","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.37358\/RC.19.7.7380","article-title":"Malondialdehyde as a Prognostic Marker in Patients with Ovarian Adenocarcinoma","volume":"70","author":"Trifanescu","year":"2019","journal-title":"Rev. Chim."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100081","DOI":"10.1016\/j.esmoop.2021.100081","article-title":"Impact of Health-Related Quality of Life (HRQoL) on Short-Term Mortality in Patients with Recurrent Ovarian, Fallopian or Peritoneal Carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): Results of a Meta-Analysis in 2209 Patients","volume":"6","author":"Armbrust","year":"2021","journal-title":"ESMO Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.3802\/jgo.2021.32.e18","article-title":"Ovarian Cancer Risk Score Predicts Chemo-Response and Outcome in Epithelial Ovarian Carcinoma Patients","volume":"32","author":"Lu","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.annonc.2020.05.019","article-title":"Prognostic Gene Expression Signature for High-Grade Serous Ovarian Cancer","volume":"31","author":"Millstein","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:16:05Z","timestamp":1760120165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["medicina59020229"],"URL":"https:\/\/doi.org\/10.3390\/medicina59020229","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}